Transcription
Hey everyone, this is Brian Jaros. I'm here at the RheumNow live booth at ACR 2026 in Orlando. And today I'll be talking to you about abstract 1892. This is clinical characteristics of flares of GCA 2-year outcomes from the SELECT GCA phase 3 trial.
So long-term data in GCA and in most of our vasculitides is always always welcome. And the SELECT GCA trial, which had a period 2, helps us understand a little bit more about what treatment beyond 1 year looks like, and specifically in patients who flare, what those flares look like.
So to kind of refresh your memory, SELECT GCA was the phase 3 trial that compared upadacitinib to placebo, with great data at week 52 that led to the ultimate approval of upadacitinib as one of our two agents that treats GCA. Now, patients after that initial phase 1 week 52 period — patients who were in remission who were off steroids — had the option to enter into a second period, another 52 weeks, where they were randomized to either stay on upadacitinib or were randomized to come off upadacitinib and go to placebo.
In this video, I'm going to talk about what the results of that study look like. So the biggest takeaway from this is the difference in flares between people who stayed on upadacitinib for that second year versus were randomized off. And again, these were people who were in remission off steroids. Only 6% of people experienced a flare if they stayed on for the second year, compared to just about 56% of patients in the placebo arm. So obviously that is a huge difference — that's very very impactful, you know, when you're counseling a patient about their risk of staying on the medication or their risk of flare of coming off. And I think, you know, it justifies what a lot of us have thought for a while: that a year of treatment for GCA is not long enough, and that these people need longer-term treatment for this relapsing disease.
Now, the study really helpfully detailed what exactly these flares look like, and we can get a lot of valuable information from that. We saw that the majority of people who flared had both a clinical flare and a biomarker flare using ESR elevation. Granted, the quantity of that ESR elevation was a bit lower in the upadacitinib group compared to the placebo group, but a vast majority still did mount a response. That sort of diminished quantity in terms of the biomarker flare was also mirrored with CRP.
Thankfully, the rates of severe flares were overall low — lower in the upadacitinib arm at 25% compared to the placebo arm at 42%. And when they look at the amount of prednisone needed to rescue or treat someone for a flare, this was also lower — about 50% lower in the upadacitinib group, where the mean average prednisone needed for treatment was about 9.5 mg in comparison to 18 mg in the placebo arm.
When you are asking what did the flares look like, what symptoms did people experience — the most common type of flare overall was actually PMR symptoms, and this was drastically reduced in the upadacitinib group, which kind of brings up interesting hypotheses. We don't have frank RCT data in PMR to say that JAK inhibitors work. But if very few patients with GCA are experiencing a PMR flare, does that give us some early insight or confidence that a JAK inhibitor might be successful for PMR? And I think that's really interesting.
The next most common type of flare, as you might assume, was cranial symptoms. And overall visual symptoms in both arms were quite low. Only one person in the upadacitinib arm and one person in the placebo arm experienced a visual sign or symptom as a manifestation of their flare.
So getting into my overall takeaways from this — again, we now know from this trial, with even more concrete data, that one year of treatment is not long enough for GCA. These people are really prone to relapse if you take them off treatment after just a year. We know that treatment with steroid-sparing therapy like upadacitinib reduces the number of severe flares, looks like it reduces the amount of prednisone needed when somebody does flare, and reassuringly, rates of vision symptoms — you know, the scariest thing that we worry about in GCA — were low in terms of the relapse quality across both arms.
That's what I have for today. I'll be signing off. We'll see you tomorrow in Orlando.
So long-term data in GCA and in most of our vasculitides is always always welcome. And the SELECT GCA trial, which had a period 2, helps us understand a little bit more about what treatment beyond 1 year looks like, and specifically in patients who flare, what those flares look like.
So to kind of refresh your memory, SELECT GCA was the phase 3 trial that compared upadacitinib to placebo, with great data at week 52 that led to the ultimate approval of upadacitinib as one of our two agents that treats GCA. Now, patients after that initial phase 1 week 52 period — patients who were in remission who were off steroids — had the option to enter into a second period, another 52 weeks, where they were randomized to either stay on upadacitinib or were randomized to come off upadacitinib and go to placebo.
In this video, I'm going to talk about what the results of that study look like. So the biggest takeaway from this is the difference in flares between people who stayed on upadacitinib for that second year versus were randomized off. And again, these were people who were in remission off steroids. Only 6% of people experienced a flare if they stayed on for the second year, compared to just about 56% of patients in the placebo arm. So obviously that is a huge difference — that's very very impactful, you know, when you're counseling a patient about their risk of staying on the medication or their risk of flare of coming off. And I think, you know, it justifies what a lot of us have thought for a while: that a year of treatment for GCA is not long enough, and that these people need longer-term treatment for this relapsing disease.
Now, the study really helpfully detailed what exactly these flares look like, and we can get a lot of valuable information from that. We saw that the majority of people who flared had both a clinical flare and a biomarker flare using ESR elevation. Granted, the quantity of that ESR elevation was a bit lower in the upadacitinib group compared to the placebo group, but a vast majority still did mount a response. That sort of diminished quantity in terms of the biomarker flare was also mirrored with CRP.
Thankfully, the rates of severe flares were overall low — lower in the upadacitinib arm at 25% compared to the placebo arm at 42%. And when they look at the amount of prednisone needed to rescue or treat someone for a flare, this was also lower — about 50% lower in the upadacitinib group, where the mean average prednisone needed for treatment was about 9.5 mg in comparison to 18 mg in the placebo arm.
When you are asking what did the flares look like, what symptoms did people experience — the most common type of flare overall was actually PMR symptoms, and this was drastically reduced in the upadacitinib group, which kind of brings up interesting hypotheses. We don't have frank RCT data in PMR to say that JAK inhibitors work. But if very few patients with GCA are experiencing a PMR flare, does that give us some early insight or confidence that a JAK inhibitor might be successful for PMR? And I think that's really interesting.
The next most common type of flare, as you might assume, was cranial symptoms. And overall visual symptoms in both arms were quite low. Only one person in the upadacitinib arm and one person in the placebo arm experienced a visual sign or symptom as a manifestation of their flare.
So getting into my overall takeaways from this — again, we now know from this trial, with even more concrete data, that one year of treatment is not long enough for GCA. These people are really prone to relapse if you take them off treatment after just a year. We know that treatment with steroid-sparing therapy like upadacitinib reduces the number of severe flares, looks like it reduces the amount of prednisone needed when somebody does flare, and reassuringly, rates of vision symptoms — you know, the scariest thing that we worry about in GCA — were low in terms of the relapse quality across both arms.
That's what I have for today. I'll be signing off. We'll see you tomorrow in Orlando.
Recommended videos
-
General Rheumatology
Can we trust AI for rheumatology decisions?
-
TNF inhibitor
TNF vs TCZ in Takayasu's Arteritis
-
General Rheumatology
FDA Safety Updates from ACR 2026

If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.